Clinical studies of RIGVIR® began in 1968 in Riga, LatviaRead More
Doniņa, S., Strēle, I., Proboka, G., Auziņš, J., Alberts, P., Jonsson, B., Venskus, D., Muceniece, A.
An oncolytic, nonpathogenic ECHO-7 virus adapted for melanoma that has not been genetically modified (RIGVIR®) is approved and registered for virotherapy, an active and specific immunotherapy, in Latvia since 2004. The present retrospective study was carried out to determine the effectiveness of RIGVIR® in substage IB, IIA, IIB and IIC melanoma patients on time to progression and overall survival…Full Article
Tilgase, A., Patetko, L., Blāķe, L., Ramata-Stunda, A., Borodušķis, M., and Alberts, P.
The role of oncolytic viruses in cancer treatment is increasingly studied. The first oncolytic virus (RIGVIR®, ECHO-7) was registered in Latvia over a decade ago. In a recent retrospective study RIGVIR® decreased mortality 4.39-6.57-fold in stage IB-IIC melanoma patients. The aims of the present study are to test the effect of RIGVIR® on cell line viability in vitro and to visualize the cellular presence of RIGVIR® by immunocytochemistry…Full Article
Alberts, P., Olmane, E., Brokāne L., Krastiņa, Z., Romanovska, M., Kupčs, K., Isajevs, S., Proboka, G., Erdmanis, R., Nazarovs, J., Venskus, D.
Oncolytic virotherapy is a recent addition to cancer treatment. Here, we describe positive treatment outcomes in three patients using RIGVIR® virotherapy…Full Article
Proboka, G., Tilgase, A., Isajevs, S., Rasa, A., Alberts, P.
Melanoma is considered an aggressive malignancy with a tendency of forming metastasis in the brain. Less than 10% of all melanoma cases present with unknown primary tumor location. This diagnose is yet to be fully understood, because there are only theoretical assumptions about the nature of the disease…Full Article